CRDF - Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022

PR Newswire

SAN DIEGO , July 5, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings at the William Blair Biotech Focus Conference 2022, which is taking place at The St. Regis New York on July 12 – 13, 2022.

The fireside chat will be pre-recorded and available on-demand beginning on Monday, July 11, 2022 . A link to the recording will available on the " Events " section of the Cardiff Oncology website.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com .

Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com

Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Amy Jobe , Ph.D
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

SOURCE Cardiff Oncology, Inc.